Taysha Gene Therapies, Inc.
TSHA
$6.85
$0.030.44%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | 171.27% | -- | 78.60% | -32.51% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 171.27% | -- | 78.60% | -32.51% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | 171.27% | -- | 78.60% | -32.51% |
| SG&A Expenses | 18.62% | 33.25% | 4.77% | 17.17% | 15.16% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 83.31% | 53.89% | 48.91% | 28.24% | -14.48% |
| Operating Income | -103.01% | -41.98% | -61.56% | -25.61% | 11.96% |
| Income Before Tax | -96.99% | -48.26% | -28.24% | -28.45% | 10.52% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -96.99% | -48.26% | -28.24% | -28.45% | 10.52% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -96.99% | -48.26% | -28.24% | -28.45% | 10.52% |
| EBIT | -103.01% | -41.98% | -61.56% | -25.61% | 11.96% |
| EBITDA | -104.33% | -42.66% | -62.47% | -26.21% | 11.94% |
| EPS Basic | -44.81% | -11.29% | 2.83% | -0.33% | 23.17% |
| Normalized Basic EPS | -50.43% | -14.50% | -19.88% | -1.14% | 25.40% |
| EPS Diluted | -44.81% | -11.29% | 2.83% | -0.33% | 23.17% |
| Normalized Diluted EPS | -50.43% | -14.50% | -19.88% | -1.14% | 25.40% |
| Average Basic Shares Outstanding | 36.14% | 33.14% | 31.92% | 27.99% | 16.46% |
| Average Diluted Shares Outstanding | 36.14% | 33.14% | 31.92% | 27.99% | 16.46% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |